AS1411

AS1411 is a novel aptamer-based investigational drug candidate under development and evaluation with the potential to treat viral based-infectious diseases and different types of cancers.  Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule and are typically created by selection from a large random sequence pool. The AS1411 aptamer is a G-rich oligonucleotide that targets and binds to nucleolin, a protein that is present on the surface of tumor cells.

The AS1411 aptamer has been tested in over 100 patients and is well tolerated with no evidence of severe side effects, with at least 7 patients having long-lasting clinical responses, where their cancers either disappeared or shrank substantially.

AS1411 is also a key component of Qualigen’s anti-nucleolin agent-conjugated nanoparticle drug candidates: ALAN, ALAN-RE and ALAN-I.